AIM Vaccine's mRNA RSV Vaccine Approved for U.S. Clinical Trials
February 27, 2025 | 07:00
The stocks in the Hong Kong pharmaceutical sector have recently shown an upward trend. As global capital flows positively into the pharmaceutical sector, PRC vaccine leader AIM Vaccine announced on February 26 that its self-developed mRNA RSV vaccine has recently received clinical trial approval from the U.S. Food and Drug Administration.
AIM Vaccine's mRNA Shingles Vaccine Submits Clinical Application to the U.S.
February 25, 2025 | 07:00
As global capital reassesses the investment value of innovative Chinese companies, the development of innovative vaccines in China is in full swing.
Mobile Version
